Pioneering a path forward
We’re dedicated to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases by rapidly advancing care and precision medicines addressing the root cause.
Learn about our translational research based on the largest known DNA database focused on obesity.
Learn about our clinical development programs with trials in patients with rare obesities linked to variants in certain genes with strong or very strong relevance to the MC4R pathway.
Dedicated to transforming the care of people living with rare genetic diseases of obesity
We’re focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger.
By targeting the MC4R pathway, we aim to develop therapeutics
for rare genetic diseases of obesity, including:
Proopiomelanocortin
|
Leptin Receptor (LEPR)
|
Bardet-Biedl
|
Alström
|
POMC or LEPR
|
Smith-Magenis
|
SRC1 Deficiency
|
MC4R Deficiency
|
SH2B1 Deficiency
|
